Related Experiment Video
Updated: Jun 23, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
[Metabolic bone diseases : what's new in 2025]
Ivan Padlina1, Andrea Trombetti1, Serge Ferrari1
1Service des maladies osseuses, Département de médecine, Hôpitaux universitaires de Genève et Faculté de médecine, 1211 Genève 14.
None:
In 2025, osteoporosis management in Switzerland benefited from the introduction of abaloparatide, an anabolic PTHrP analogue that effectively reduces the risk of vertebral and non-vertebral fractures, with reimbursement criteria identical to those of romosozumab. Zoledronate, administered preventively only twice at a five-year interval in recently menopausal, non-osteoporotic women, lowers 10-year fracture risk by about 40 %. Calcium and/or vitamin D supplements are now subject to reimbursement restrictions. Burosumab, an anti-FGF23 antibody, has become the treatment of choice for X-linked hypophosphatemic rickets, though access remains limited in Switzerland. Finally, artificial intelligence is emerging as a valuable tool for radiographic diagnosis and opportunistic screening of osteoporotic fractures.
Related Concept Videos
What is the Skeletal System?
Bone Remodeling
Osteoclasts in Bone Remodeling
The Functions of the Skeletal System
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling and Repair

